Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.49 |
| ▸ | ACACB | O00763 | 6/20 | 0.48 |
| ▸ | PARP1 | P09874 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4444461 | 0.88 | PTPN1 (0.45) | PTPN1ACACBPARP1KDM4ETSHR | |
| SCHEMBL4443192 | 0.86 | P2RY1 (0.50) | ACACBKDM4EP2RY1KMT2AMEN1 | |
| SCHEMBL14122641 | 0.85 | CARM1 (0.60) | ACACBKDM4ETSHRP2RY1KMT2A | |
| SCHEMBL4982048 | 0.81 | KDR (0.61) | KDM4ETSHRP2RY1KMT2AMEN1 | |
| SCHEMBL27959646 | 0.80 | PNMT (0.58) | KDM4EKMT2AMEN1ALDH1A1SMN1; SMN2 | |
| SCHEMBL29870452 | 0.80 | PNMT (0.58) | KDM4EKMT2AMEN1ALDH1A1SMN1; SMN2 | |
| SCHEMBL17607343 | 0.80 | ACACB (0.58) | ACACB | |
| SCHEMBL14147238 | 0.80 | KDR (0.53) | KDM4ETSHRKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL9605558 | 0.79 | KDR (0.53) | ACACBKDM4ETSHRKMT2AMEN1 | |
| SCHEMBL9605547 | 0.78 | KDR (0.70) | KDM4ETSHRP2RY1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8338455-B2 | Pyridines or pyrimidines having 4-(hydrogenated 1-pyridyl- or hydrogenated 1-isoquinolyl rings, e.g., N-(4-chlorophenyl)-2-(pyridin-4-ylmethyl)-1,2,3,4-tetrahydroisoquinoline-5-carboxamide; kinase inhibitors; inflammation, angiogenesis and cancer | AMGEN INC. (US) | 2012-12-25 | — | — | US | disclosed |
| EP-2118088-B1 | Heterocyclic compounds and their use in treating inflammation, angiogenesis and cancer | AMGEN INC (US) | 2012-05-30 | — | — | EP | disclosed |
| US-20080161346-A1 | Compounds and methods of use | AMGEN INC. (US) | 2008-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161346-A1 | Compounds and methods of use | VHL, VEGFA, FLT1 | PTPN1 1056/4885ACACB 1289/4885PARP1 1882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.